News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVRBF) Announces That New Simeprevir Data Will be Presented at the American Association for Study of Liver Diseases Meeting


11/4/2013 9:42:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that new data will be presented on the investigational protease inhibitor simeprevir (TMC435) in treatment-naïve genotype 1 chronic hepatitis C patients and in treatment -experienced patients with compensated liver disease. These data will be presented at the ongoing Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place during November 1 to 5 in Washington, D.C.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES